-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60

Benzinga·10/02/2026 10:57:44
Listen to the news
Raymond James analyst Tiago Fauth initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $60.